Y-mAbs Therapeutics appoints Peter Pfreundschuh as CFO

Y-mAbs Therapeutics announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer.”Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pretargeted Radioimmunotherapy, or SADA-PRIT, technology platform,” said Mr. Rossi. “With Peter on board as our new U.S.-based Chief Financial Officer, we believe we are in a strong position to make strategic decisions that will serve our mission of improving the lives of patients with cancer and other serious diseases. Peter brings a wealth of leadership experience across the healthcare sector with deep experience in developing and commercializing novel pharmaceutical products, and we are excited to welcome him to our team.”